FY2026 EPS Estimates for Revvity Lifted by Zacks Research

Revvity Inc. (NYSE:RVTY) – Analysts at Zacks Research boosted their FY2026 EPS estimates for shares of Revvity in a research report issued on Friday, September 4th. Zacks Research analyst Team now expects that the company will post earnings of $5.40 per share for the year, up from their prior forecast of $5.38. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Revvity’s current full-year earnings is $5.37 per share. Zacks Research also issued estimates for Revvity’s Q1 2027 earnings at $1.19 EPS, Q2 2027 earnings at $1.53 EPS, FY2027 earnings at $5.93 EPS, Q1 2028 earnings at $1.35 EPS and FY2028 earnings at $6.62 EPS.

A number of other brokerages also recently commented on RVTY. Evercore restated an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. KeyCorp increased their price objective on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a research report on Friday. TD Cowen reissued a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, Wolfe Research started coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Four equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $114.77.

Revvity Stock Down 2.1%

RVTY opened at $127.45 on Monday. Revvity has a 52 week low of $81.22 and a 52 week high of $133.00. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The business has a 50 day moving average price of $117.12 and a two-hundred day moving average price of $102.75. The company has a market cap of $14.22 billion, a PE ratio of 60.69, a P/E/G ratio of 2.37 and a beta of 1.09.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. During the same quarter in the prior year, the business earned $1.18 EPS. Revvity’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS.

Institutional Trading of Revvity

A number of institutional investors have recently bought and sold shares of RVTY. Ascentis Independent Advisors acquired a new position in shares of Revvity during the 1st quarter worth $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the 2nd quarter valued at about $32,000. MUFG Securities EMEA plc acquired a new stake in Revvity in the 2nd quarter valued at about $34,000. SJS Investment Consulting Inc. increased its holdings in Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after acquiring an additional 521 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Revvity during the 2nd quarter valued at about $49,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s payout ratio is currently 13.33%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.